DG2 Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: understanding NICE guidance

NICE has assessed Elucigene FH20 and LIPOchip to help the NHS decide whether to use these products.

Elucigene FH20 and LIPOchip are tests that detect DNA changes linked to familial hypercholesterolaemia.

NICE has said that Elucigene FH20 and LIPOchip are not recommended for confirming familial hypercholesterolaemia because another test called comprehensive genetic analysis is more likely to accurately confirm the diagnosis at a reasonable cost.

NICE has also said that Elucigene FH20 and LIPOchip are not recommended for testing relatives of people with familial hypercholesterolaemia. Another test called targeted sequencing is more likely to accurately detect familial hypercholesterolaemia in these relatives and is less expensive.

This page was last updated: 20 January 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.